Safety and effectiveness of stiripentol in patients with Dravet syndrome: A prospective, 3-year, postmarketing surveillance study.
Yuki Kitamura, Hiroaki Ohyabu, Tatsuo Miura and 4 others
PMID 39923248WHAT IT FOUND
Stiripentol was continued by 71.9% of patients over 3 years, with 37.7% showing marked or moderate overall improvement.
Somnolence was the most common side effect. Growth remained within normal ranges despite frequent decreased appetite.
Key findings
0171.9% of patients continued stiripentol use after 156 weeks.
02The rate of overall improvement (marked or moderate) was 37.7%.
03Somnolence was the most frequent adverse drug reaction at 37.3%, and decreased appetite was the most frequent serious reaction at 4.6%.
STILL TO COME
How it was doneWhat they found
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
This was an uncontrolled observational study, so it is impossible to separate the effect of stiripentol from the effects of the concomitant clobazam, sodium valproate, and other treatments all patients received. Diagnosis of Dravet syndrome was made by individual physicians without strict central verification, which may affect the accuracy of the patient population. Effectiveness assessments were less rigorous than in clinical trials, relying on physician judgment and caregiver diaries which had some missing data. The study was conducted in Japan, and genetic factors like CYP2C19 polymorphism prevalence may differ from other populations.
Declared interests
The study was a postmarketing surveillance required by Japanese regulations. Stiripentol was created by Biocodex. The text does not explicitly state Biocodex's role in the design or analysis of this specific surveillance report, but the context implies industry-sponsored monitoring.
The easy way to misread this
Do not attribute the observed seizure reduction or improvement solely to stiripentol. Every patient in this study was also taking clobazam and sodium valproate, and many took other medications or therapies, so the contribution of any single component cannot be separated.